SCHEMBL8081937

SCHEMBL8081937

CC(C)c1cc(C(=O)c2cccc(Cl)c2)cc(C(C)C)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.69
GABRB1 P18505 3/20 0.69
POLB P06746 1/20 0.50
BCL2 P10415 1/20 0.48
MCL1 Q07820 1/20 0.48
LMNA P02545 3/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
PARP1 P09874 1/20 0.46
MAOB P27338 1/20 0.46
SLC6A2 P23975 4/20 0.46
CHRNA1 P02708 2/20 0.46
CHRNG P07510 2/20 0.46
CHRNB1 P11230 2/20 0.46
CHRNB2 P17787 2/20 0.46
CHRNB4 P30926 2/20 0.46
SLC6A4 P31645 2/20 0.46
CHRNA3 P32297 2/20 0.46
CHRNA4 P43681 2/20 0.46
SLC6A3 Q01959 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8081993 0.85 GABRA1 (0.64) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL8286757 0.83 GABRA1 (0.71) GABRA1GABRB1POLBBCL2MCL1
SCHEMBL2417465 0.82 GABRA1 (0.70) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL29405385 0.82 GABRA1 (1.00) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL13639493 0.81 GABRA1 (0.69) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL8080419 0.81 GABRA1 (0.69) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL8077296 0.81 GABRA1 (0.69) GABRA1GABRB1POLBBCL2MCL1
SCHEMBL28078271 0.81 GABRA1 (0.78) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL8077084 0.81 GABRA1 (0.63) GABRA1GABRB1BCL2MCL1LMNA
SCHEMBL8067378 0.81 GABRA1 (0.63) GABRA1GABRB1BCL2MCL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2520290-B1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE LLC (US) 2014-12-10 EP disclosed
EP-2520290-A1 Propofol analogs, process for their preparation, and methods of use Abraxis BioScience, LLC (US) 2012-11-07 EP disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
WO-2005063665-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885POLB 2115/4885
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885POLB 2115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.